IVVD
Invivyd, Inc.
A biopharmaceutical company making monoclonal antibody medicines for viral diseases, Invivyd's only commercial product is PEMGARDA (pemivibart), a preventive antibody given to certain immunocompromised adults and teens at risk of COVID-19. It was founded in 2020 as Adagio Therapeutics, a spin-out of the antibody-discovery firm Adimab, and renamed Invivyd in 2022. The name hints at its mission of building antibodies that outpace fast-mutating viruses.
CUSIP: 00534A102HealthcareUS1 holder
Total Value
$16.55M
Total Shares
18.97M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
